Sequestrant Compositions for Gut-Selective Metabolite Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders associated with intestinal hyperpermeability or leaky gut, such as autism, are inadequate as they fail to effectively address the underlying intestinal metabolites contributing to behavioral symptoms.
Innovation Solution
Development of sequestrant compositions comprising biocompatible, non-digestible particles that bind to intestinal metabolites in the gut, forming a complex which is then eliminated, thereby reducing their absorption and interaction with tissues, using materials like activated carbon, clay, or polymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-absorbable polymers are used to sequester intestinal metabolites, then behavioral symptoms of neurological disorders are treated, but the complexity of the treatment composition increases
Solution Approach 1:
The sequestrant composition is designed to bind multiple different intestinal metabolites (phenolic compounds, indoles, skatoles, thiols, and their derivatives) simultaneously using a single multipurpose polymer formulation, eliminating the need for multiple separate treatments
Solution Approach 2:
The patent modifies polymer parameters including molecular weight (1,000 to 1,000,000 Daltons), functional groups (carboxyl, hydroxyl, amino), and physical form (particles, films, coatings) to optimize binding effectiveness while maintaining simplicity of administration
2Object-affected harmful factors
If sequestrant compositions are administered to bind intestinal metabolites, then metabolite absorption is reduced, but the quantity of substance to be excreted increases
Solution Approach 1:
The sequestrant composition selectively extracts and removes harmful intestinal metabolites from the gut lumen by binding them to polymer chains, concentrating them into a form that can be efficiently eliminated in feces
Solution Approach 2:
The bound metabolite-polymer complex is designed to be excreted intact in feces, preventing metabolite reabsorption and allowing for regular elimination without requiring additional recovery steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sequestrant compositions effectively reduce levels of intestinal metabolites associated with behavioral symptoms, providing a treatment for neurological disorders by preventing their absorption and promoting their excretion, thus alleviating symptoms.
Implementation Method 1
These compositions comprise a multiplicity of biocompatible particles and/or polymers which are non-digestible and non-absorbable by the digestive tract of the subject. The sequestrant compositions bind to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex
Data Source
AI summary
The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.